Nitrosated Active Pharmaceutical Ingredients - Lessons Learned?

Area of Science:

• Pharmaceutical Chemistry
• Drug Quality Control
• Regulatory Science

Background:

• Recent findings of N-nitrosodialkylamines in pharmaceuticals revealed limitations in existing quality control measures.
• These impurities, including nitrosamine drug-substance-related impurities (NDSRIs), are not covered by standard compendial tests for related substances, residual solvents, or heavy metals.
• NDSRIs arise from reactions between vulnerable amino moieties in APIs and nitrite contaminants, often from excipients.

Purpose of the Study:

• To address the emerging issue of N-nitrosodialkylamines and NDSRIs in pharmaceutical products.
• To highlight the inadequacy of current pharmacopoeial quality control tests for these specific impurities.
• To review the formation, toxicity, and mitigation strategies for NDSRIs.

Main Methods:

• Review of recent findings on nitrosamine occurrence in APIs and drug products.
• Analysis of the classification of N-nitrosodialkylamines under ICH M7 guideline for mutagenic impurities.
• Examination of NDSRI formation mechanisms, particularly involving excipient contaminants.

Main Results:

• N-nitrosodialkylamines are a significant class of drug impurities not adequately controlled by traditional pharmacopoeial methods.
• NDSRIs are formed through specific chemical reactions involving API structures and nitrite contaminants.
• Regulatory authorities now require thorough risk assessments for these impurities.

Conclusions:

• Existing pharmacopoeial quality control tests are insufficient to detect and control N-nitrosodialkylamines and NDSRIs.
• Understanding the formation pathways of NDSRIs is crucial for effective mitigation.
• Adherence to ICH M7 guidelines and robust risk assessment are essential for ensuring drug quality and patient safety.